<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Ministry of Commerce</title>
	<atom:link href="http://www.tapanray.in/tag/ministry-of-commerce/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Data Exclusivity in India: Innovation Catalyst or Affordability Risk for Indian Pharma?</title>
		<link>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma</link>
		<comments>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 06 Dec 2025 14:33:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life-saving]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry of Commerce]]></category>
		<category><![CDATA[ministry of health]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11008</guid>
		<description><![CDATA[For over four decades, India’s pharmaceutical industry has been built on a powerful moral and economic proposition: that life-saving medicines should be affordable, accessible, and globally available from Indian manufacturing prowess. This principle transformed India into the “pharmacy of the developing &#8230; <a href="http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make in India” Image of Pharma Needs An Early Makeover</title>
		<link>http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-in-india-image-of-pharma-needs-an-early-makeover</link>
		<comments>http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/#comments</comments>
		<pubDate>Mon, 20 Apr 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AllianceBoots]]></category>
		<category><![CDATA[Amerisource –Bergen]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Celesio]]></category>
		<category><![CDATA[CVS Caremark]]></category>
		<category><![CDATA[Data Integrity.]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[makeover]]></category>
		<category><![CDATA[McKesson]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry of Commerce]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[pharma export]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacy distributors]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Stefano Pessina]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Walgreen]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6549</guid>
		<description><![CDATA[“It is never too late to be what you might have been” - George Elliot The chronicle of events since the last couple of years or so, related to ‘Make in India’ image of the local drug industry, have been instrumental &#8230; <a href="http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
